[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Friends Research Institute, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":119},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,67,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100653453","supporting-treatment-for-opioids-and-recovery-capital-storc---r61-phase-100653453",false,"NCT07787039","Supporting Treatment for Opioids and Recovery Capital (STORC) - R61 Phase","Empowering Support Persons to Enhance the Recovery Capital of Postpartum Women With Opioid Use Disorder - R61 Phase","STORC R61","Inclusion Criteria:\n\n* must be biological females\n* must be currently within 6 weeks postpartum\n* must be able to read, write, and speak English at a 6th-grade level\n* must be diagnosed and receiving treatment for, or willing to receive treatment for opioid use disorder at the PROUD clinic\n* must identify a support person who also consents to participate. Patient participants must identify prospective support persons in order to complete consent\n\nExclusion Criteria:\n\n* pregnancy\n* planned discharge to a long-term inpatient care facility (e.g., hospice)\n* hospitalization for a suicide attempt\n* major mental health disorder that requires treatment before OAT can be considered\n* stillbirth or neonatal death of the index pregnancy\u002Finfant, as determined from the obstetric record.","FEMALE","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","We are studying whether training an identified support person and providing patient navigation (i.e. a peer recovery specialist assisting you with finding the right support) after delivery can increase \"recovery capital\"-the resources that help people with opioid use disorder (OUD) stay in treatment and recover. This study will build upon the research team's prior work in conducting research among pregnant and parenting women with OUD. This project will be directed by the research team at Friends Research Institute in close collaboration with their research and clinical partners at the University of Pennsylvania in Philadelphia, PA. A two-phase study is proposed with an initial 1-year developmental phase (R61) that will develop and pilot test STORC to include support person training. A second 4-year phase (R33) will test STORC in a parallel, two-arm, randomized controlled trial design at two study sites.",[27],"Opioid Use Disorder",[29],"Patient Navigation","RECRUITING","2026-10-06",{"date":33,"type":34},"2026-10-09","ACTUAL",{"date":36,"type":34},"2026-09-26",{"date":38,"type":21},"2027-01-30",{"name":40,"class":41},"Friends Research Institute, Inc.","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100539638","phase-3-buprenorphine-for-individuals-in-jail-100539638","NCT06306443","Buprenorphine for Individuals in Jail","A Comparative Effectiveness Trial of Sublingual Versus Extended-release Buprenorphine With Individuals Leaving a Carceral Setting","Inclusion Criteria:\n\n* Adult male or female inmates at participating jail who are eligible for release within 120 days (sentenced and\u002For pretrial \\[note: individuals who might be sentenced to state\u002Ffederal prison will be excluded\\]); Those individuals who are pre-trial and\u002For sentenced who are completing their sentence in the community (probation, parole, home detention, electronic monitoring, drug or other treatment court \\[or equivalent\\]) will be eligible to participate;\n* History of opioid use disorder (meeting DSM-5 criteria of moderate or severe opioid use disorder at the time of incarceration; individuals not meeting the opioid-disorder criterion will be eligible if they were treated in an opioid agonist treatment program during the year before incarceration);\n* Suitability for XR-B and\u002For SL-B treatment as determined by medical evaluation;\n* Willingness to enroll in XR-B or SL-B treatment in jail and continue in the community;\n* Planning to live in Baltimore City or the Baltimore Region;\n\nExclusion Criteria:\n\n* Liver function test levels greater than 5 times normal (if we are unable to obtain labs, a determination by the study physician will be made to allow inclusion);\n* Active medical illness that may make participation hazardous (e.g., unstable diabetes, heart disease; moderate to severe renal impairment; adequately treated medical conditions are acceptable);\n* Conditions or medications that may predispose to QTc prolongation (personal or family history of long QT syndrome, hypokalemia, medications that prolong QTc interval, e.g., macrolide antibiotics, azole antifungal compounds, anti-arrythmics, antipsychotics and antidepressant);\n* Untreated psychiatric disorder that may make participation hazardous (e.g., untreated psychosis, bipolar disorder with mania; adequately treated psychiatric disorders and appropriate psychotropic medications will be allowed);\n* History of allergic reaction to buprenorphine;\n* Suicidal ideation (within the past 6 months);\n* Inability to pass a study enrollment quiz; and\n* Currently receiving non-buprenorphine MOUD in jail (methadone, naltrexone).",true,"ALL",{"count":53,"type":21},240,[55],"PHASE3","This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-released from jail to either XR-B (n=120) or SL-B (n=120) treatment in jail followed by 6-months of post-release buprenorphine treatment, a 7-month safety visit, and a final long-term follow-up at 12-months.",[27],"2026-06-02",{"date":60,"type":34},"2026-06-04",{"date":62,"type":34},"2025-06-20",{"date":64,"type":21},"2029-04-30",{"name":40,"class":41},2,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100560156","addressing-racial-disparities-in-opioid-overdose-using-peer-recovery-coach-training-and-mhealth-platform-100560156","NCT06573476","Addressing Racial Disparities in Opioid Overdose Using Peer Recovery Coach Training and mHealth Platform","Addressing Racial Disparities in Opioid Overdose Deaths Using an Open Source Peer Recovery Coach Training and Multimodal Mobile Health Platform","Inclusion Criteria:\n\n* ≥18 years of age\n* fluent in English\n* self-reported non-prescription opioid use \\\u003C30 days prior to consent\n* provision of informed consent\n* planned stay in NYC ≥3 months\n* Black and\u002For Latinx race\u002Fethnicity\n* positive urine toxicology for opioids per EMR records or study staff administered random saliva drug testing\n* diagnosis of OUD per the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)\n* self-reported interest in initiating buprenorphine in primary care, or elsewhere.\n\nExclusion Criteria:\n\n* inability to comprehend text content written at a 3rd grade reading level\n* physical or visual disability preventing mobile phone use","99 Years",{"count":76,"type":21},180,[24],"The study aims to adapt an existing Cultural Structural Humility (CSH) training into a video format for peer recovery coaches (PRCs) and refine an AI-driven texting tool to reinforce the training. After refining these tools using user-centered design, a pilot test will be conducted to assess their impact on the uptake of opioid treatment and social services. The study will also evaluate the feasibility and effectiveness of the intervention to inform future large-scale trials.",[27],[27,81,82,83,84,85,86,87],"Peer Recovery Coach","Cultural Structural Humility","mHealth","People With Opioid Use Disorder","OUD","PWOUD","mHealth Intervention","2026-05-25",{"date":90,"type":34},"2026-05-27",{"date":92,"type":34},"2025-06-25",{"date":94,"type":21},"2027-03-15",{"name":40,"class":41},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":42},"100613100","navstar-implementation-effectiveness-trial-across-a-health-system-100613100","NCT07262190","NavSTAR Implementation Effectiveness Trial Across a Health System","Implementing a Patient Navigation Intervention Across a Health System to Improve Outcomes for Patients With Opioid Use Disorder","Philly NavSTAR","Inclusion Criteria:\n\n1. age 18 or older;\n2. current DSM-5 criteria for moderate to severe OUD;\n3. willing and able to provide informed consent in English.\n\nExclusion Criteria:\n\n1. enrollment in OUD treatment 30-days prior to hospitalization;\n2. residency outside the City of Philadelphia;\n3. pregnancy;\n4. planned discharge to a long-term inpatient care facility (e.g., hospice);\n5. hospitalization for a suicide attempt.",{"count":105,"type":21},720,[24],"Patient Navigation (PN) interventions following hospitalization can improve outcomes for people with opioid use disorder treatment. Delivering PN interventions on a wide scale requires many resources and coordination across institutions. This will use an evidence-based process to find solutions to these significant barriers by engaging community, hospital, and patient partners. This study is being conducted to learn more about how to implement NavSTAR, a patient navigation intervention for people with opioid use disorder, across a health system. The research team showed in a previous study with 400 participants that NavSTAR significantly increased entry into opioid use disorder treatment, reduced readmissions to the hospital, and was highly cost- effective compared to treatment as usual. This study will first pilot NavSTAR with 32 patient participants across 4 hospitals in the City of Philadelphia. Then, a large trial with 720 patient participants will be conducted to see if people who need the intervention are reached, and a sustainable plan will be created to continue the intervention after the grant award period.",[27],[110],"patient navigation","2025-11-21",{"date":113,"type":34},"2025-12-03",{"date":115,"type":34},"2025-10-27",{"date":117,"type":21},"2029-08-01",{"name":40,"class":41},""]